Compare MORN & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | RDY |
|---|---|---|
| Founded | 1984 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 11.6B |
| IPO Year | 2005 | N/A |
| Metric | MORN | RDY |
|---|---|---|
| Price | $217.81 | $14.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $333.33 | $16.90 |
| AVG Volume (30 Days) | 296.7K | ★ 938.9K |
| Earning Date | 10-29-2025 | 01-22-2026 |
| Dividend Yield | ★ 0.83% | 0.50% |
| EPS Growth | ★ 16.18 | 9.95 |
| EPS | ★ 8.80 | 0.79 |
| Revenue | $2,395,400,000.00 | ★ $3,851,623,984.00 |
| Revenue This Year | $8.79 | $6.16 |
| Revenue Next Year | $7.52 | $2.57 |
| P/E Ratio | $24.81 | ★ $17.87 |
| Revenue Growth | 7.76 | ★ 14.10 |
| 52 Week Low | $202.89 | $12.26 |
| 52 Week High | $365.00 | $16.17 |
| Indicator | MORN | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 57.67 |
| Support Level | $213.53 | $13.64 |
| Resistance Level | $219.62 | $14.20 |
| Average True Range (ATR) | 4.43 | 0.16 |
| MACD | 1.32 | 0.05 |
| Stochastic Oscillator | 89.38 | 98.25 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.